Jung, Myung-Ho Kim, Hwan Choi, Won-Kyoung El-Gamal, Mohammed I. Park, Jin-Hun Yoo, Kyung Ho Sim, Tae Bo Lee, So Ha Baek, Daejin Hah, Jung-Mi Cho, Jung-Hyuck Oh, Chang-Hyun 2024-01-20T20:04:16Z 2024-01-20T20:04:16Z 2021-09-05 2009-12-01 0960-894X https://pubs.kist.re.kr/handle/201004/131889 Synthesis of a new series of diarylureas and amides having pyrrolo[2,3-d]pyrimidine scaffold is described. Their in vitro antiproliferative activities against A375 human melanoma cell line and HS 27 fibroblast cell line were tested and the effect of substituents on pyrrolo[2,3-d]pyrimidine was investigated. The newly synthesized compounds, except N-acetyl derivatives (Id, Ie, and Im), generally showed superior or similar activity against A375 to Sorafenib. Among all of these derivatives, compounds Iq and Ir having imidazole and morpholine moieties, respectively, showed the most potent antiproliferative activity against A375. (C) 2009 Published by Elsevier Ltd. English Pergamon Press Ltd. REFRACTORY SOLID TUMORS FACTOR RECEPTOR INHIBITOR RAF KINASE SUBSTITUTED UREAS PHASE-I BAY-43-9006 THERAPY PHARMACOKINETICS INTERLEUKIN-2 PATHWAY Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line Article 10.1016/j.bmcl.2009.10.051 1 Bioorganic & Medicinal Chemistry Letters, v.19, no.23, pp.6538 - 6543 Bioorganic & Medicinal Chemistry Letters 19 23 6538 6543 scie scopus 000271430400008 2-s2.0-71749118193 Chemistry, Medicinal Chemistry, Organic Pharmacology & Pharmacy Chemistry Article REFRACTORY SOLID TUMORS FACTOR RECEPTOR INHIBITOR RAF KINASE SUBSTITUTED UREAS PHASE-I BAY-43-9006 THERAPY PHARMACOKINETICS INTERLEUKIN-2 PATHWAY Pyrrolo[2,3-d]pyrimidine A375 HS 27 Antiproliferative activity Melanoma